Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Has $3.84 Million Position in Illumina, Inc. (NASDAQ:ILMN)
Mitsubishi UFJ Kokusai Asset Management Co. Ltd. reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.6% during the second quarter, Holdings Channel reports. The firm owned 22,130 shares of the life sciences company’s stock after selling 2,623 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Illumina were worth $3,840,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Advocacy Wealth Management Services LLC acquired a new stake in shares of Illumina during the first quarter valued at approximately $102,000. Gemmer Asset Management LLC increased its stake in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the last quarter. Advisory Services Network LLC acquired a new stake in shares of Illumina during the first quarter valued at approximately $117,000. Patten Group Inc. increased its stake in shares of Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. increased its stake in shares of Illumina by 11.3% in the second quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after buying an additional 100 shares during the last quarter. 93.81% of the stock is currently owned by institutional investors.
Illumina, Inc. (NASDAQ ILMN) opened at 194.25 on Friday. The company has a market cap of $28.36 billion, a PE ratio of 38.97 and a beta of 0.83. Illumina, Inc. has a one year low of $119.37 and a one year high of $199.95. The stock has a 50 day moving average price of $179.63 and a 200 day moving average price of $173.73.
Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company had revenue of $662 million for the quarter, compared to analyst estimates of $642.38 million. During the same quarter in the prior year, the business posted $0.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, equities analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
WARNING: This report was posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/mitsubishi-ufj-kokusai-asset-management-co-ltd-has-3-84-million-position-in-illumina-inc-nasdaqilmn/1481326.html.
ILMN has been the topic of several research analyst reports. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective on the stock in a research note on Monday, April 17th. Cantor Fitzgerald raised their price objective on Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 26th. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Morgan Stanley reaffirmed an “underweight” rating and set a $122.00 price objective (up previously from $115.00) on shares of Illumina in a research note on Monday, July 10th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and set a $175.00 price objective (up previously from $165.00) on shares of Illumina in a research note on Saturday, April 29th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. Illumina currently has a consensus rating of “Hold” and a consensus price target of $177.01.
In other Illumina news, EVP Omead Ostadan sold 1,671 shares of the stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $195.26, for a total value of $326,279.46. Following the completion of the sale, the executive vice president now owns 24,571 shares in the company, valued at approximately $4,797,733.46. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $180.24, for a total transaction of $3,604,800.00. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at approximately $97,181,082.24. The disclosure for this sale can be found here. Insiders sold a total of 134,010 shares of company stock worth $23,946,015 in the last 90 days. 1.60% of the stock is currently owned by company insiders.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.